Is LPCN a buy?
Sarah Silva
Updated on February 07, 2026
Is LPCN a buy?
Out of 3 analysts, 2 (66.67%) are recommending LPCN as a Strong Buy, 1 (33.33%) are recommending LPCN as a Buy, 0 (0%) are recommending LPCN as a Hold, 0 (0%) are recommending LPCN as a Sell, and 0 (0%) are recommending LPCN as a Strong Sell. What is LPCN’s earnings growth forecast for 2021-2023?
Who bought lipocine stock?
Top 10 Owners of Lipocine Inc
| Stockholder | Stake | Shares bought / sold |
|---|---|---|
| The Vanguard Group, Inc. | 4.27% | +230,794 |
| BlackRock Fund Advisors | 1.77% | -57,837 |
| Geode Capital Management LLC | 0.86% | +156,873 |
| Columbia Management Investment Ad… | 0.80% | -31,000 |
Will LPCN get FDA approval?
(NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration (“FDA”) has granted tentative approval to TLANDO, its oral testosterone product for testosterone replacement therapy (“TRT”) in adult males indicated for …
Is lipocine a good buy?
Lipocine has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Will lipocine stock go up?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Lipocine Inc have a median target of 2.75, with a high estimate of 10.00 and a low estimate of 2.50. The median estimate represents a +96.43% increase from the last price of 1.40.
Will pulmatrix stock go up?
Will Pulmatrix stock price grow / rise / go up? Yes. The PULM stock price can go up from 0.757 USD to 0.879 USD in one year.
What is the stock price of Lipocine Inc?
Price Action: LPCN shares are down 13.7% at $1.18 during the market session on the last check Wednesday.
When does Lipocine report third quarter 2020 results?
By John Vandermosten NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Third Quarter 2020 Operational and Financial Results On November 10, 2020 Lipocine (NASDAQ:LPCN) filed its third quarter 2020 10-Q and posted its earnings release for the three month period ending September 30, 2020.
When did the FDA give Lipocine TLANDO tentative approval?
By John Vandermosten NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT FDA Grants Tentative Approval to Tlando After multiple extensions from the August 2020 target action date, the FDA granted tentative approval of Lipocine’s (NASDAQ: LPCN) Tlando on December 8th.
Is there a patent case between Lipocine and Clarus?
Market open. The U.S. District Court for the District of Delaware has granted Clarus Therapeutics’ motion for summary judgment against remaining patents in a patent infringement case brought by Lipocine Inc (NASDAQ: LPCN) regarding Clarus’s oral testosterone replacement product, Jatenzo.
Price Action: LPCN shares are down 13.7% at $1.18 during the market session on the last check Wednesday.
By John Vandermosten NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Third Quarter 2020 Operational and Financial Results On November 10, 2020 Lipocine (NASDAQ:LPCN) filed its third quarter 2020 10-Q and posted its earnings release for the three month period ending September 30, 2020.
By John Vandermosten NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT FDA Grants Tentative Approval to Tlando After multiple extensions from the August 2020 target action date, the FDA granted tentative approval of Lipocine’s (NASDAQ: LPCN) Tlando on December 8th.
What was the outcome of the Lipocine patent case?
Federal Circuit Judge found all of the asserted Lipocine patents claims invalid. Clarus’s defense of inequitable conduct remains pending, and its disposition is expected to be addressed by Clarus and the Court at a future date.
